Last reviewed · How we verify
GLPG1972 multiple ascending doses — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GLPG1972 multiple ascending doses (GLPG1972 multiple ascending doses) — Galapagos NV.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GLPG1972 multiple ascending doses TARGET | GLPG1972 multiple ascending doses | Galapagos NV | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GLPG1972 multiple ascending doses CI watch — RSS
- GLPG1972 multiple ascending doses CI watch — Atom
- GLPG1972 multiple ascending doses CI watch — JSON
- GLPG1972 multiple ascending doses alone — RSS
Cite this brief
Drug Landscape (2026). GLPG1972 multiple ascending doses — Competitive Intelligence Brief. https://druglandscape.com/ci/glpg1972-multiple-ascending-doses. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab